IMPACT Intervention
Primary Purpose
Diabetes Mellitus, Type 2
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
IMPACT intervention
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring primary health care, patient-centered care, poverty areas, vulnerable populations, Glycated Hemoglobin A
Eligibility Criteria
Inclusion Criteria:
- Patients with type 2 diabetes
- Inclusion HbA1c > 7.5%
- Live in Hauts de Chambéry, Biollay or Renaudie district
- Be able to give written consent
Exclusion Criteria:
- Severe cognitive or psychological disorder that may affect study understanding
- Pregnant or breastfeeding women
- Had IMPACT intervention in the previous 24 months
- Concurrent participation in another study
- Concurrent participation in another diabetes educational care program
- Life expectancy less than 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention group
Control group
Arm Description
IMPACT intervention
Usual care
Outcomes
Primary Outcome Measures
HbA1c
Change in glycated haemoglobin (HbA1c)
Secondary Outcome Measures
HbA1c
Change in glycated haemoglobin (HbA1c)
Weight
Change in weight
Body mass index
Change in body mass index
Body fat mass (Bioelectrical impedance analysis)
Change in body fat mass
Body fat percentage (Bioelectrical impedance analysis)
Change in body fat percentage
Muscle mass (Bioelectrical impedance analysis)
Change in muscle mass.
Lipids - HDL cholesterol
Change in HDL cholesterol
Lipids - LDL cholesterol
Change in LDL cholesterol
Lipids - triglycerides
Change in triglycerides
Full Information
NCT ID
NCT04616053
First Posted
October 27, 2020
Last Updated
November 1, 2020
Sponsor
Pole de Sante Chambery Nord
1. Study Identification
Unique Protocol Identification Number
NCT04616053
Brief Title
IMPACT Intervention
Official Title
A Randomised Controlled Trial to Evaluate the Effectiveness of a Multidisciplinary Team Intervention on Glycaemic Control for Disadvantaged Type 2 Diabetes Patients in France.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2021 (Anticipated)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
March 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pole de Sante Chambery Nord
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Introduction :
The prevalence of type 2 diabetes is increasing in France, especially in deprived districts.
The Itineraires Medico-sociaux Programme d'Accompagnement sur un Territoire (IMPACT) intervention is intended for disadvantaged patients with a chronic disease (not only type 2 diabetes).
The IMPACT intervention offers coordinated and patient-centered care by a multidisciplinary team with an empowerment approach. This personalised intervention lasts 6 months.
This study aims to evaluate the effect of 6 months IMPACT intervention on glycaemic control (glycated haemoglobin - HbA1c) of patients with type 2 diabetes in deprived districts.
Method :
This will be a randomised, controlled, parallel group, multicenter, open-label trial. 140 adults with type 2 diabetes will be randomised in two arms : IMPACT intervention group (n : 70) and usual care group (n : 70). The primary outcome is change in glycated haemoglobin (HbA1c) from baseline to 6 months. The primary outcome will be analysed using a linear mixed effects model.
Detailed Description
This will be a randomised, controlled, parallel group, multicenter, open-label trial. Patients will be recruited among patients with type 2 diabetes referred to the IMPACT intervention.
144 patients will be randomised in two arms : IMPACT intervention group (n : 72) and usual care group (n : 72).
IMPACT intervention : a referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program. The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patients with his health administrative procedures.
Patients will have 3 visits. First visit (inclusion visit) : investigator collects baseline characteristics (sociodemographic data, comorbidity, treatment, diabetes complications, weight, height, body mass index, impedancemetry, HbA1c, lipids, creatinine, albuminuria/creatinuria ratio). Then the patient will be randomised.
Second visit (midpoint visit) : investigator collects weight, BMI, impedancemetry, HbA1c and adverse events Third visit (end point visit) : investigator collects weight, BMI, impedancemetry, HbA1c, lipids and adverse events.
Analysis : The primary outcome is change in glycated haemoglobin (HbA1c) from baseline to 6 months. The primary outcome will be analysed using a linear mixed effects model. Study groups, districts, time, group-time interaction and district-group interaction will be included as fixed effects. The model will include patients as a random effect. Sub-group analysis will be made with baseline HbA1c, sex, age, Epices score (French precarity score) and diabetes duration. The robustness of the model will be tested by replacing missing data with multiple imputation methods. The same statistical modelling approach will be used for the secondary outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
primary health care, patient-centered care, poverty areas, vulnerable populations, Glycated Hemoglobin A
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
140 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
IMPACT intervention
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Usual care
Intervention Type
Behavioral
Intervention Name(s)
IMPACT intervention
Intervention Description
A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
Primary Outcome Measure Information:
Title
HbA1c
Description
Change in glycated haemoglobin (HbA1c)
Time Frame
From baseline to 6 months
Secondary Outcome Measure Information:
Title
HbA1c
Description
Change in glycated haemoglobin (HbA1c)
Time Frame
From baseline to 3 months
Title
Weight
Description
Change in weight
Time Frame
At Months 3 and 6 from baseline
Title
Body mass index
Description
Change in body mass index
Time Frame
At Months 3 and 6 from baseline
Title
Body fat mass (Bioelectrical impedance analysis)
Description
Change in body fat mass
Time Frame
At Months 3 and 6 from baseline
Title
Body fat percentage (Bioelectrical impedance analysis)
Description
Change in body fat percentage
Time Frame
At Months 3 and 6 from baseline
Title
Muscle mass (Bioelectrical impedance analysis)
Description
Change in muscle mass.
Time Frame
At Months 3 and 6 from baseline
Title
Lipids - HDL cholesterol
Description
Change in HDL cholesterol
Time Frame
From baseline to 6 months
Title
Lipids - LDL cholesterol
Description
Change in LDL cholesterol
Time Frame
From baseline to 6 months
Title
Lipids - triglycerides
Description
Change in triglycerides
Time Frame
From baseline to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with type 2 diabetes
Inclusion HbA1c > 7.5%
Live in Hauts de Chambéry, Biollay or Renaudie district
Be able to give written consent
Exclusion Criteria:
Severe cognitive or psychological disorder that may affect study understanding
Pregnant or breastfeeding women
Had IMPACT intervention in the previous 24 months
Concurrent participation in another study
Concurrent participation in another diabetes educational care program
Life expectancy less than 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Donatien Talon, Resident
Phone
+33679230064
Email
donatien.talon@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
22683130
Citation
Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, Manns B, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012 Jun 16;379(9833):2252-61. doi: 10.1016/S0140-6736(12)60480-2. Epub 2012 Jun 9.
Results Reference
background
PubMed Identifier
25188210
Citation
Attridge M, Creamer J, Ramsden M, Cannings-John R, Hawthorne K. Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2014 Sep 4;(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.
Results Reference
background
PubMed Identifier
30552277
Citation
Captieux M, Pearce G, Parke HL, Epiphaniou E, Wild S, Taylor SJC, Pinnock H. Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews. BMJ Open. 2018 Dec 14;8(12):e024262. doi: 10.1136/bmjopen-2018-024262.
Results Reference
background
Learn more about this trial
IMPACT Intervention
We'll reach out to this number within 24 hrs